Sigmoid Septum: Cause and Clinical Significance
A sigmoid septum is primarily caused by age-related and hypertension-related left ventricular hypertrophy that begins at the basal interventricular septum, representing a manifestation of adverse ventricular-arterial coupling rather than true hypertrophic cardiomyopathy. 1
Pathophysiological Mechanism
The basal/outlet ventricular septum develops prominent hypertrophy because this region experiences the greatest regional wall stress during systolic contraction. The impaired ventricular function relates specifically to high late systolic pressure rather than peak systolic pressure, making this a consequence of adverse ventricular-arterial coupling 1.
Key Causative Factors
Primary drivers include:
- Advanced age - The sigmoid septum is predominantly seen in elderly patients (mean age ~73 years in type 2 sigmoid septum) 2
- Systemic hypertension - Present in approximately 85% of patients with significant sigmoid septum 2
- Impaired renal function - Lower glomerular filtration rates correlate with more prominent septal bulging 2
The definitive Framingham Heart Study of 3,562 subjects demonstrated that upper septal hypertrophy correlated directly with age and blood pressure, but after adjusting for risk factors, it was unrelated to cardiovascular disease or mortality at 15 years 1. This confirms the benign nature of isolated sigmoid septum.
Distinguishing from Hypertrophic Cardiomyopathy
Critical distinction: While sigmoid septum may superficially resemble HCM, it is fundamentally different:
Sigmoid Septum Characteristics:
- Isolated basal septal hypertrophy (≥13mm in men, ≥12mm in women)
- Exceeds ≥50% of mid-septal thickness 2
- Causative sarcomeric mutations rarely found 1
- Predominantly affects elderly hypertensive patients
- Lower prevalence of repolarization abnormalities on ECG (18.2% vs higher in HCM) 2
- Different fibrosis pattern on cardiac MRI 2
When Diagnostic Ambiguity Exists:
The 2024 Canadian guidelines specifically address this common conundrum: Isolated basal septal hypertrophy (sigmoid septum) in elderly individuals with hypertension often creates diagnostic uncertainty, and the distinction between benign and pathologic conditions may not be clear 3.
Practical approach:
- Severe hypertension with mild symmetric hypertrophy → favors hypertensive heart disease
- Mild hypertension with asymmetric and/or severe wall thickening (>18mm) → favors HCM 3
- Cardiac MRI is particularly helpful for differential diagnosis when uncertainty persists 2
Clinical Implications
Hemodynamic Considerations
Some patients with sigmoid septum can develop dynamic left ventricular outflow tract (LVOT) obstruction under specific conditions 4, 5:
- Occurs with hypercontractile states or inotropic stimulation
- Approximately 50% may show hyperresponse to dobutamine stress 5
- Can cause systolic anterior motion (SAM) of mitral valve during provocation 4
- May produce hypotension during exercise or stress testing 6
However, this is functionally distinct from HCM - the obstruction is typically provoked rather than resting, and the underlying pathophysiology differs.
Morphological Diversity
Recent cardiac CT studies reveal that sigmoid septum demonstrates bidirectional septal bulging (both antero-superior and medial directions) that:
- Varies considerably in extent among normal hearts 7
- Deforms and narrows the LVOT without affecting the virtual basal ring morphology 7
- Correlates with deep aortic wedging (non-coronary sinus to inferior epicardium distance) 7
Common Pitfalls to Avoid
- Do not automatically diagnose HCM based solely on basal septal thickness in elderly hypertensive patients
- Do not overlook the clinical context - age, hypertension severity, and ECG findings are critical
- Do not assume benignity without evaluation - some patients may develop provocable LVOT obstruction requiring beta-blocker therapy 4
- Do not rely on echocardiography alone when diagnostic uncertainty exists - cardiac MRI provides superior tissue characterization 2
Management Implications
For isolated sigmoid septum without obstruction:
- No specific cardiac therapy required beyond standard hypertension management
- Prognosis is benign when adjusted for cardiovascular risk factors 1
- Routine cardiac surveillance beyond standard hypertensive heart disease monitoring is unnecessary
For sigmoid septum with provocable LVOT obstruction:
- Beta-blockers can eliminate obstruction signs 4
- Avoid inotropic stimulation and volume depletion
- Exercise counseling regarding symptoms during exertion